Ventyx Biosciences, Inc. (VTYX)
Largest Insider Buys in Sector
VTYX Stock Price History Chart
VTYX Stock Performance
About Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the …
Insider Activity of Ventyx Biosciences, Inc.
Over the last 12 months, insiders at Ventyx Biosciences, Inc. have bought $0 and sold $221,938 worth of Ventyx Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Ventyx Biosciences, Inc. have bought $40M and sold $53.31M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,250,000 shares for transaction amount of $20M was made by Cormorant Asset Management, LP () on 2021‑10‑25.
List of Insider Buy and Sell Transactions, Ventyx Biosciences, Inc.
| 2024-04-02 | Sale | CEO AND PRESIDENT | 4,312 0.0075% | $5.40 | $23,299 | -52.29% | ||
| 2024-04-02 | Sale | CHIEF BUSINESS OFFICER | 1,651 0.0029% | $5.40 | $8,921 | -52.29% | ||
| 2024-04-02 | Sale | CHIEF SCIENTIFIC OFFICER | 1,651 0.0029% | $5.40 | $8,921 | -52.29% | ||
| 2024-04-02 | Sale | CHIEF FINANCIAL OFFICER | 1,405 0.0024% | $5.40 | $7,592 | -52.29% | ||
| 2023-12-20 | Sale | CEO and President | 58,860 0.1014% | $2.12 | $124,660 | +21.72% | ||
| 2023-12-20 | Sale | Chief Business Officer | 5,293 0.0091% | $2.12 | $11,210 | +21.72% | ||
| 2023-12-20 | Sale | Chief Scientific Officer | 17,628 0.0304% | $2.12 | $37,334 | +21.72% | ||
| 2023-10-09 | Sale | 49,152 0.0835% | $30.03 | $1.48M | -91.33% | |||
| 2023-10-09 | Sale | 10 percent owner | 49,152 0.0835% | $30.03 | $1.48M | -91.33% | ||
| 2023-10-05 | Sale | Chief Executive Officer | 30,000 0.0476% | $29.11 | $873,231 | -90.95% | ||
| 2023-10-03 | Sale | Chief Business Officer | 15,000 0.0245% | $29.98 | $449,699 | -90.91% | ||
| 2023-10-03 | Sale | Chief Scientific Officer | 10,000 0.0163% | $29.99 | $299,933 | -90.91% | ||
| 2023-09-18 | Sale | 56,665 0.0964% | $37.81 | $2.14M | -92.11% | |||
| 2023-09-18 | Sale | 10 percent owner | 56,665 0.0964% | $37.81 | $2.14M | -92.11% | ||
| 2023-09-05 | Sale | Chief Executive Officer | 30,000 0.0515% | $32.61 | $978,343 | -87.95% | ||
| 2023-09-05 | Sale | Chief Business Officer | 15,000 0.0258% | $32.61 | $489,109 | -87.95% | ||
| 2023-09-05 | Sale | Chief Scientific Officer | 10,000 0.0172% | $32.60 | $325,960 | -87.95% | ||
| 2023-09-05 | Sale | Chief Financial Officer | 26,472 0.0455% | $32.61 | $863,334 | -87.95% | ||
| 2023-08-31 | Sale | See Remarks | 11,900 0.0203% | $33.64 | $400,354 | -87.79% | ||
| 2023-08-08 | Sale | See Remarks | 3,494 0.0059% | $32.86 | $114,810 | -86.04% |
Insider Historical Profitability
| Royston Aaron | 3997269 5.653% | $1.88 | 1 | 0 | <0.0001% | |
| venBio Global Strategic Fund III, L.P. | 10 percent owner | 3997269 5.653% | $1.88 | 1 | 0 | <0.0001% |
| Cormorant Asset Management, LP | 1410303 1.9945% | $1.88 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Citadel Advisors LLC | $31.8M | 8.36 | 5.89M | +38.09% | +$8.77M | 0.02 | |
| BlackRock | $20.61M | 5.32 | 3.75M | -1.77% | -$370,909.01 | <0.0001 | |
| The Vanguard Group | $20.38M | 5.26 | 3.71M | -0.97% | -$200,491.50 | <0.0001 | |
| Deerfield Management | $19.48M | 5.02 | 3.54M | New | +$19.48M | 0.05 | |
| Farallon Capital | $17.43M | 4.5 | 3.17M | New | +$17.43M | 0.12 |